Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 14, 2005

View Archived Issues

Neuropeptide Y Y2 antagonist effective in rats with ethanol dependence

Neuroprotective effects of thiazolidinediones in a preclinical model of stroke

RP-101 reported to improve survival in patients with advanced pancreatic cancer

Phase II data on the benefits of PT-141 in female sexual dysfunction

Putative antidepressant LY-367265 inhibits glutamate release in rat cortex

Update on the efficacy of rasburicase in the prevention of hyperuricemia in cancer patients

Ondansetron improves auditory gating in schizophrenic patients

Positive findings in phase II study of ProMune plus chemotherapy in NSCLC

ReceptoPharm plans phase IIb/III study of RPI-78M in adrenomyeloneuropathy

Phase IIb/III DIAS2 study begins for desmoteplase in acute ischemic stroke

Boehringer Ingelheim discontinues development of bivatuzumab mertansine

Adderall XR sales suspended in Canada

Pharmacokinetic study of TRANSDUR-based sufentanil patch completes dosing

Phase II study of Durect's postoperative pain relief depot product progresses

Positive phase III results for Nuvigil

XP-13512 enters phase IIb study for restless legs syndrome

SPA agreement for phase III study of Cloretazine in relapsed AML

Vical completes SPA for Allovectin-7

SOT-107 receives Japanese orphan drug status

Three series of chemokine CCR4 receptor modulators claimed by AstraZeneca

New anticoagulant agents reported by Bristol-Myers Squibb

Aventis imparts new tubulin polymerization inhibitors for cancer therapy

Novel antiinflammatory chalcones patented by AtheroGenics

Bristol-Myers Squibb patent covers new antiinflammatory agents

Metabotropic glutamate (mGluR5) receptor antagonists described in patent literature

First anti-HIV dual CCR5/CXCR4 antagonist described / News in Context

New title added to the Drug R&D Backgrounders topic list - Osteoarthritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...